The acute systemic toxicity of thallium in rats produces oxidative stress: attenuation by metallothionein and Prussian blue

BioMetals ◽  
2021 ◽  
Author(s):  
Laura Anaya-Ramos ◽  
Araceli Díaz-Ruíz ◽  
Camilo Ríos ◽  
Marisela Mendez-Armenta ◽  
Sergio Montes ◽  
...  
2015 ◽  
Vol 146 (2) ◽  
pp. 244-253 ◽  
Author(s):  
Michael L. Paffett ◽  
Katherine E. Zychowski ◽  
Lianne Sheppard ◽  
Sarah Robertson ◽  
John M. Weaver ◽  
...  

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 1040-1040
Author(s):  
Jorge Toblli ◽  
Gabriel Cao ◽  
Margarita Angerosa ◽  
Roberto Cacchione

Abstract Abstract 1040 Background: Iron(III) polymaltose complex (IPC) shows similar efficacy to ferrous sulfate for the treatment of iron deficiency anemia but with superior tolerability. The stable structure of IPC prevents unregulated uptake of iron from the gut, avoiding an increase in non-transferrin bound iron with associated oxidative stress. IPC similars have been developed which vary in structure from the originator IPC preparation (Maltofer®, IPCM). A direct comparison between the originator and IPC similars in their potential to induce oxidative stress has not been performed. In this study, we compared acute and early toxicity in the gastrointestinal (GI) tract and liver in healthy rats randomized to IPCM, an IPC similar (Vitalix, IPCV) or a control arm. Methods: LD50 values were determined by administering single increasing doses of IPCM or IPCV (each n=12) and counting deaths at 24 hours. Three groups of rats (each n=12) then received doses equivalent to 10% of LD50 for IPCM (280 mg iron/kg/day) or IPCV (280 mg iron/kg/day), or tap water (controls) for 28 days. Iron-induced lesions in the GI tract were scored: 1, superficial 1–5 hemorrhagic points; 2, superficial 6–10, hemorrhagic points; 3, sub-mucosal hemorrhagic lesions with small erosions; 4, severe hemorrhagic lesions and some invasive lesions. Iron deposits (Prussian blue) and tissue ferritin in the liver and small intestine were assessed by immunohistochemistry. Ferritin immunostaining in the small intestine was scored: 1, none; 2, mild; 3, moderate; 4, very intense. Results: LD50 was the same for IPCM and IPCV (>2800 mg iron/kg). Animals treated with IPCV had lower food consumption and body weight vs those treated with IPCM and controls. IPCV was associated with increased serum iron and transferrin saturation vs the IPCM group, suggesting bypass of the regulated iron uptake system. Microscopically, the villi/crypt ratio and the number of Goblet cells per villi in the small intestine were significantly lower with IPCV vs IPCM or controls, and the number of eosinophils per villi was increased in IPCV-treated animals. Gross anatomy and microscopy findings showed that IPCV- treated animals experienced variable degrees of inflammation in the GI tract while the IPCM and control groups showed no lesions. Ferritin immunostaining of liver tissue indicated that iron was appropriately stored in IPCM-treated within Kupffer's cells (Prussian blue). Ferritin deposits in the small intestine were also higher with IPCM. Differences were statistically inferior for IPCV versus IPCM for clinical and iron parameters, gross anatomy, microscopic findings and ferritin immunostaining (Table). Conclusions: IPCV showed the same LD50 as IPCM, but considerably greater early GI tract toxicity. Increased numbers of eosinophils in the IPCV group suggest an allergic component of the small intestine injury in these groups. Markers of iron transport and distribution indicated less well controlled uptake and storage following ingestion of IPCV compared to IPCM. The increased levels of ferritin deposits in the small intestine of IPCM-treated animals suggests that excess iron is stored in the gut wall instead of saturating the iron transport mechanism and increasing non-transferrin bound iron levels. Disclosures: Toblli: Vifor (International) Ltd: Consultancy, Research Funding.


2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Yan Zhang ◽  
Yifei Yin ◽  
Wei Zhang ◽  
Hongyan Li ◽  
Taixia Wang ◽  
...  

Abstract Background As one typical cardiovascular disease, atherosclerosis severely endanger people’ life and cause burden to people health and mentality. It has been extensively accepted that oxidative stress and inflammation closely correlate with the evolution of atherosclerotic plaques, and they directly participate in all stages of atherosclerosis. Regarding this, anti-oxidation or anti-inflammation drugs were developed to enable anti-oxidative therapy and anti-inflammation therapy against atherosclerosis. However, current drugs failed to meet clinical demands. Methods Nanomedicine and nanotechnology hold great potential in addressing the issue. In this report, we engineered a simvastatin (Sim)-loaded theranostic agent based on porous manganese-substituted prussian blue (PMPB) analogues. The biomimetic PMPB carrier could scavenge ROS and mitigate inflammation in vitro and in vivo. Especially after combining with Sim, the composite Sim@PMPB NC was expected to regulate the processes of atherosclerosis. As well, Mn2+ release from PMPB was expected to enhance MRI. Results The composite Sim@PMPB NC performed the best in regulating the hallmarks of atherosclerosis with above twofold decreases, typically such as oxidative stress, macrophage infiltration, plaque density, LDL internalization, fibrous cap thickness and foam cell birth, etc. Moreover, H2O2-induced Mn2+ release from PMPB NC in atherosclerotic inflammation could enhance MRI for visualizing plaques. Moreover, Sim@PMPB exhibited high biocompatibility according to references and experimental results. Conclusions The biomimetic Sim@PMPB theranostic agent successfully stabilized atherosclerotic plaques and alleviated atherosclerosis, and also localized and magnified atherosclerosis, which enabled the monitoring of H2O2-associated atherosclerosis evolution after treatment. As well, Sim@PMPB was biocompatible, thus holding great potential in clinical translation for treating atherosclerosis. Graphic abstract


2020 ◽  
Vol 170 ◽  
pp. 112669 ◽  
Author(s):  
Daniel Rojas ◽  
Juan F. Hernández-Rodríguez ◽  
Flavio Della Pelle ◽  
Michele Del Carlo ◽  
Dario Compagnone ◽  
...  

2014 ◽  
Vol 68 ◽  
pp. 78-86 ◽  
Author(s):  
Fernanda C. Campos ◽  
Vanessa J. Victorino ◽  
Marli Cardoso Martins-Pinge ◽  
Alessandra L. Cecchini ◽  
Carolina Panis ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1996-1996
Author(s):  
Rabaa AL-Rousan ◽  
Anjaiah Katta ◽  
Satyanarayana Paturi ◽  
Brent Kidd ◽  
Kamran Manzoor ◽  
...  

Abstract Abstract 1996 Poster Board I-1018 Background: Iron overload occurs under conditions such as primary (hereditary) hemochromatosis and secondary iron overload (hemosiderosis) and is associated with an increased risk of developing liver fibrosis, cirrhosis, and hepatocellular carcinoma. Deferasirox is a novel oral chelator with high iron-binding potency and selectivity. Here we investigate the ability of deferasirox to remove excessive hepatic iron and prevent or reverse iron induced hepatic injury. Methods: Adult male Mongolian Gerbils were randomly divided into three groups: control, iron overload, and iron overload + deferasirox treatment (n = 8 / group). Iron overload animals received iron dextran 100mg/kg i.p /5d for 10 wks while deferasirox was given 100mg/kg/d p.o for 1-,3-, or 9- months. Hepatic iron levels were determined by inductively coupled plasma atomic emission spectrometry and Prussian blue staining was performed to examine iron deposition in the corresponding tissues. Immunoblot and immunohistochemical analyses for markers of oxidative stress were employed to assess effects of deferasirox treatment on hepatic protein oxidation and superoxide levels. TUNEL assay was employed to examine the extent of hepatic apoptosis. Results: Compared to the non-treated iron overload group, deferasirox treatment reduced hepatic iron levels by 21.3%, 43.5%, and 47.4% after 1, 3, and 9 months of treatment, respectively (p<0.05). Prussian blue staining and histological analysis detected frequent iron deposition, evidence of hepatic damage, and lipid accumulation in hepatic tissue of the iron overloaded group. Iron deposition was significantly diminished with deferasirox treatment and no evidence of lipid accumulation was observed. Immunoblotting demonstrated that iron overload caused 2- fold increase in hepatic ferritin expression (p< 0.05) which was reduced by 47.5% following three months of deferasirox treatment (p< 0.05). In addition, deferasirox significantly reduced hepatic protein oxidation and superoxide abundance. The percentage of TUNEL-positive nuclei in the deferasirox treated livers was 41.0% lower than that of iron overloaded group (p<0.05). Conclusions: These findings suggest that chronic deferasirox treatment may decrease iron-induced hepatic oxidative stress and apoptosis. Decrease in ROS accumulation in the liver may be the possible mechanism of this protective effect. Further studies are underway to delineate specific mechanisms. Disclosures: No relevant conflicts of interest to declare.


Nanoscale ◽  
2019 ◽  
Vol 11 (41) ◽  
pp. 19497-19505 ◽  
Author(s):  
Renwu Zhou ◽  
Peiyu Wang ◽  
Yanru Guo ◽  
Xiaofeng Dai ◽  
Shaoqing Xiao ◽  
...  

This work demonstrated the efficacy of Prussian blue analogue nanoparticles as effective scavengers of reactive oxygen species under plasma-controlled cellular stress conditions and a booster of ethanol fuel production by yeast fermentation.


Sign in / Sign up

Export Citation Format

Share Document